<DOC>
	<DOCNO>NCT01115790</DOCNO>
	<brief_summary>The primary purpose Parts A B study evaluate safety toxicity prexasertib ( inhibitor checkpoint kinase 1 [ chk 1 ] ) participant advance metastatic cancer ( Part A ) , squamous cell cancer head neck squamous cell cancer tumor type ( Part B ) . Part C study evaluate prexasertib three different group participant ; squamous cell cancer head neck recur spread part body , squamous non-small cell lung cancer recur spread , squamous cell cancer anus curable exist therapy .</brief_summary>
	<brief_title>A Phase 1 Study Participants With Advanced Cancer</brief_title>
	<detailed_description>Part C add per protocol amendment ( February , 2013 ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<criteria>Must appropriate candidate experimental therapy , determine investigator , available standard therapy fail Have adequate organ function Prior Therapies : Systemic treatment : must discontinue previous systemic treatment cancer recover acute effect therapy . Participants must discontinue mitomycinC nitrosourea therapy least 42 day discontinue cytotoxic therapy least 28 day prior study enrollment . Radiation therapy surgery : must complete least 4 week study enrollment Part A : Must diagnosis cancer advance metastatic Part B : Must histologically confirm squamous cell cancer head neck must squamous cell cancer tumor type Part C : Must histological diagnosis squamous cell cancer head neck , histological cytological diagnosis squamous nonsmallcell lung cancer , histological diagnosis Stage IIIB ( N2 N3 ) Stage IV squamous cell cancer anus curable local therapy Must available duration study willing follow study procedure If participant reproductive potential , must agree use medically approve contraceptive precaution study three month follow last dose study drug If participant female childbearing potential , must negative serum urine pregnancy test within 7 day first dose study drug must breast feeding Must take unapproved drug treatment indication within last 28 day prior start study treatment Must active symptomatic fungal , bacterial viral infection , include human immunodeficiency virus ( HIV ) Hepatitis A , B , C Must serious heart condition , congestive heart failure , unstable angina pectoris , heart attack within last three month Must systolic blood pressure &lt; 90 millimeter mercury ( mmHg ) recurrent symptomatic orthostatic hypotension Must family history long QTc syndrome take drug know cause QTc prolongation Torsades de Pointes Must serotoninsecreting carcinoid tumor prior history druginduced serotonin syndrome Must acute leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>